Annual Financials for Revolution Medicines Inc.
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
- | 20.17M | 50.04M | 42.98M | 29.39M | |
Sales Growth |
- | - | 148.16% | -14.10% | -31.62% | |
Cost of Goods Sold (COGS) incl. D&A |
1.19M | - | - | - | 7.33M | |
COGS excluding D&A |
- | - | - | - | - | |
Depreciation & Amortization Expense |
1.19M | 1.76M | 3.34M | 6.55M | 7.33M | |
Depreciation |
1.19M | 1.57M | 2.27M | 5.48M | 6.26M | |
Amortization of Intangibles |
- | 198,000 | 1.07M | 1.07M | 1.07M | |
COGS Growth |
- | - | - | - | - | |
Gross Income |
(1.19M) | - | - | - | 22.06M | |
Gross Income Growth |
- | - | - | - | - | |
Gross Profit Margin |
- | - | - | - | 75.05% | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
29.94M | 58.33M | 100.22M | 147.14M | 210.07M | |
Research & Development |
26.59M | 51.08M | 91.16M | 128.57M | 182.8M | |
Other SG&A |
3.36M | 7.25M | 9.06M | 18.56M | - | |
SGA Growth |
- | 94.82% | 71.82% | 46.81% | 42.77% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | 2.52M | - | - | - | |
EBIT after Unusual Expense |
- | (42.45M) | - | - | - | |
Non Operating Income/Expense |
- | - | (597,000) | - | - | |
Non-Operating Interest Income |
105,000 | 777,000 | 2.19M | 2.24M | 929,000 | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
103,000 | 116,000 | 106,000 | 71,000 | 12,000 | |
Interest Expense Growth |
- | 12.62% | -8.62% | -33.02% | -83.10% | |
Gross Interest Expense |
103,000 | 116,000 | 106,000 | 71,000 | 12,000 | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(31.13M) | (41.79M) | (52.04M) | (108.53M) | (187.09M) | |
Pretax Income Growth |
- | -34.25% | -24.52% | -108.56% | -72.39% | |
Pretax Margin |
- | - | - | - | -636.58% | NA |
Income Tax |
- | - | (4.37M) | (371,000) | - | |
Income Tax - Current Domestic |
- | - | (4.37M) | (371,000) | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(31.13M) | (41.79M) | (47.66M) | (108.16M) | (187.09M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(31.13M) | (41.79M) | (47.66M) | (108.16M) | (187.09M) | |
Net Income Growth |
- | -34.25% | -14.06% | -126.92% | -72.98% | |
Net Margin Growth |
- | - | - | - | -636.58% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(31.13M) | (41.79M) | (47.66M) | (108.16M) | (187.09M) | |
Preferred Dividends |
3.76M | 7.03M | 14.24M | 2.22M | - | |
Net Income Available to Common |
(34.89M) | (48.82M) | (61.9M) | (110.38M) | (187.09M) | |
EPS (Basic) |
(0.59) | (0.83) | (1.05) | (1.66) | (2.57) | |
EPS (Basic) Growth |
- | -39.93% | -26.81% | -57.96% | -55.05% | |
Basic Shares Outstanding |
59M | 59M | 59M | 66.6M | 72.81M | |
EPS (Diluted) |
(0.59) | (0.83) | (1.05) | (1.66) | (2.57) | |
EPS (Diluted) Growth |
- | -39.93% | -26.81% | -57.96% | -55.05% | |
Diluted Shares Outstanding |
59M | 59M | 59M | 66.6M | 72.81M | |
EBITDA |
(29.94M) | (38.17M) | (50.18M) | (104.15M) | (180.68M) | |
EBITDA Growth |
- | -27.47% | -31.48% | -107.55% | -73.47% | |
EBITDA Margin |
- | - | - | - | -614.75% | NA |